Methotrexate Safety Tips (7.31.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Four Decades of Gout Management
During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued primary attention.
https://t.co/ddzj3RktDD https://t.co/x7o0HfWqHa
Dr. John Cush @RheumNow( View Tweet )
New, Advanced Therapies in Gout
New, Advanced Therapies in Gout explores the rapidly evolving therapeutic landscape beyond conventional urate-lowering therapy.
https://t.co/0uNK0nOEp6 https://t.co/YD7tQu2QrT
Dr. John Cush @RheumNow( View Tweet )
QD Clinic: Addressing Severe Gout Flares
Dr. Eric Dein, Summit, NJ, discusses a difficult-to-treat case of gout.
https://t.co/tochY0BUBj https://t.co/9hQ13cDY9s
Dr. John Cush @RheumNow( View Tweet )
Gout & Metabolic Syndrome
Dr. John Fitzgerald, Los Angeles, hates the expression "It's only Gout."
https://t.co/0JipL3kgcM https://t.co/jszxYAfZwa
Dr. John Cush @RheumNow( View Tweet )
Four Decades of Gout Management
During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued, primary attention.
https://t.co/pTcEtEfQtc https://t.co/yK79xyrEHI
Dr. John Cush @RheumNow( View Tweet )
Treatment goals in gout: aim for remission!
Rheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice. Recently, G-CAN (the Gout and Crystal Arthritis Network), endorsed a https://t.co/PP2NBqvo7E
Dr. John Cush @RheumNow( View Tweet )
Tips for safe use of allopurinol
https://t.co/Yn1u1bEj4F https://t.co/lMWPI9OsVe
Dr. John Cush @RheumNow( View Tweet )
Gout: Diagnosis
The diagnosis of gout - labs, imaging and polarized microscopy, created by @MithuRheum for RheumNow.
https://t.co/s8gkANFJSB https://t.co/pkUeFLG5if
Links:
Dr. John Cush @RheumNow( View Tweet )
Future therapies (in development) for gout - the goal is durable crystal depletion.
Created by: Dr. Aravind Palraj @rheumat_aravind for RheumNow.
https://t.co/yeCSAnHiY2 https://t.co/nH8f2Y3hNP
Dr. John Cush @RheumNow( View Tweet )
Calcium Pyrophosphate Deposition Dz new terminology from 2026 G-CAN consensus. Preferred:
- acute CPP crystal arthritis
- Chronic CPP crystal arthritis
- Chronic CPP crystal arthritis
- OA w/ CPP
- Chondrocalcinosis (xray)
* Pseudogout is obsolete
https://t.co/bsztXz9UDs https://t.co/GOey5YmKif
Dr. John Cush @RheumNow( View Tweet )
New GoutStop cards - print and give to your gout patients!
https://t.co/Bh0IuM5tzu https://t.co/j5rQJStSnu
Links:
Dr. John Cush @RheumNow( View Tweet )
Uricase-Targeted Therapies in Gout
https://t.co/RB6Yj4oY9a https://t.co/NrWq6Y93Hg
Dr. John Cush @RheumNow( View Tweet )
Four Decades of Gout Management
During this month-long campaign on Gout, we have documented many significant changes in our approach to gout, as well as many unmet needs and deficiencies that merit our continued, primary attention. We are all familiar with the famous 1905 quote, “Those who cannot remember the past
Read Article
When Gout Flares, So Does the Cardiovascular System
We have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title https://t.co/HCUQVaor4f
Dr. John Cush @RheumNow( View Tweet )
2 T2T RCTs of 383 gout pts starting allopurinol - 31% had tophi. At 12 mos achieving target uric acid (<0.36mmol/L) was same in pts with and without tophi (70.3 vs 73.6), as was the %gout flares in month 11 (71.4% vs 79.7%; p=0.21). Allopurinol T2T success not influenced by https://t.co/zr7K8Y2Bqz
Dr. John Cush @RheumNow( View Tweet )
Treatment goals in gout: aim for remission!
Rheumatologists are used to the concept of disease remission as this is a treatment goal we use for many chronic rheumatic diseases in our clinical practice. Recently, G-CAN (the Gout and Crystal Arthritis Network), endorsed a
Read Article
Evidence-Based Dietary Recommendations for Gout
Gout, historically referred to as the “disease of kings,” was once associated with a lifestyle of excess. Today, it is more appropriate to refer to gout as a “disease of commoners,” as it is the most common inflammatory arthritis https://t.co/uIrSeOjxJZ
Dr. John Cush @RheumNow( View Tweet )
Tips for safe use of allopurinol
These are tips and hopefully the patients are abstaining from moderate alcohol and are not tipsy! Here are 5 tips that may not be totally obvious.
Read Article
Pragmatism in Gout: How therapeutic choices can have multiple benefits
Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ
Dr. John Cush @RheumNow( View Tweet )
Uricase-Targeted Therapies in Gout
In most mammals, uricase catalyzes the oxidation of uric acid to allantoin, a highly soluble compound easily excreted by the kidneys. But humans lack functional uricase, leaving xanthine oxidase inhibitors (allopurinol/febuxostat) as first-line urate-lowering therapy (ULT). Uricase-based
Read Article
Calcium Pyrophosphate Deposition Dz new terminology from 2026 G-CAN consensus. Preferred:
- acute CPP crystal arthritis
- Chronic CPP crystal arthritis
- Chronic CPP crystal arthritis
- OA w/ CPP
- Chondrocalcinosis (xray)
* Pseudogout is obsolete
https://t.co/L95N2ObHr3 https://t.co/ST7RkJa8BR
Dr. John Cush @RheumNow( View Tweet )
When Gout Flares, So Does the Cardiovascular System
We have spent decades teaching that a gout flare is a joint problem: a hot, swollen, painful joint that we treat with anti-inflammatory drugs and move on from (i.e., the treat to avoid symptoms strategy). The campaign title says it well — gout is more than flares. I would add
Read Article
UK primary care database (2000–21) gout study of new colchicine initiators (n 31,478) vs noninitiators (mean 60 yrs, BMI 30), follow-up of 4.5 yrs. Colchicine use had a signif. 12% lower risk of Joint Arthroplasty (HR 0.88); 23% lower TJA in knee/hip OA (HR 0.77) https://t.co/bT07lUYBB2
Dr. John Cush @RheumNow( View Tweet )
Chikungunya Club Meeting (7.24.2026)
Dr. Jack Cush reviews the news, journal reports from the past week on RheumNow.com.
Read ArticleTherapeutic Updates
Watch our 'Systemic Burden of Gout' series as part of this month's Gout More than Flares campaign. Videos include: Gout Management in Patients with CKD, Gout and CVD, and Gout & Obesity.
Read Post
Recent Blogs
Dr. Jack Cush reviews Gout in this continuing series for Advanced Practice Rheum. Review the companion slide deck here.
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
Imagine that 100 years from now, your great granddaughter, an eminent rheumatologist, reviews the history of rheumatoid arthritis mimics.
Read Post
Podcasts
TU: Systemic Burden of Gout Part 2 (24 plus)
Gout Lessons from the Clinic Part 3
Systemic Burden of Gout Part 1
